COVID-19 and Paxlovid Treatment in Pregnant Women
Author Information
Author(s): Tseng Chun-Han, Lin Chih-Wei, Tsai Pei-Yin, Su Mei-Tsz
Primary Institution: National Cheng Kung University Hospital
Hypothesis
What is the effect of Paxlovid on viral load in pregnant women with COVID-19?
Conclusion
Saliva is a useful diagnostic tool for COVID-19 in pregnant women, and those treated with Paxlovid showed a significant decrease in viral load.
Supporting Evidence
- Saliva specimens had a detection rate of 83.8% for COVID-19.
- Viral load decreased significantly in the Paxlovid group compared to the non-antiviral group.
- Salivary PCR Ct values were significantly higher than nasopharyngeal swabs in the Paxlovid group.
Takeaway
This study shows that pregnant women can use saliva to test for COVID-19, and taking Paxlovid helps reduce the virus in their bodies.
Methodology
Pregnant women with COVID-19 were divided into two groups: those receiving Paxlovid and those receiving no antiviral treatment, and their viral loads were compared using salivary PCR.
Potential Biases
Potential selection bias due to pre-existing conditions in the Paxlovid group.
Limitations
The study had limitations including inconsistent quality of self-collected saliva samples and a limited sample size.
Participant Demographics
Median age of participants was 32 years; 25.4% received initial vaccination series only, and 34.5% received a booster.
Statistical Information
P-Value
0.021
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website